AU2021282287A1 - Cancer treatment strategies using arenavirus vectors - Google Patents

Cancer treatment strategies using arenavirus vectors Download PDF

Info

Publication number
AU2021282287A1
AU2021282287A1 AU2021282287A AU2021282287A AU2021282287A1 AU 2021282287 A1 AU2021282287 A1 AU 2021282287A1 AU 2021282287 A AU2021282287 A AU 2021282287A AU 2021282287 A AU2021282287 A AU 2021282287A AU 2021282287 A1 AU2021282287 A1 AU 2021282287A1
Authority
AU
Australia
Prior art keywords
construct
effective amount
patient
weeks
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021282287A
Other languages
English (en)
Inventor
Ursula BERKA
Donna Edwards
Andy Hwang
Corinne IACOBUCCI
Kianoosh KATCHAR
Henning Lauterbach
Igor MATUSHANSKY
Klaus Orlinger
Katia SCHLIENGER
Sarah Schmidt
Michael Schwendinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neotrail Therapeutics Inc
Original Assignee
Neotrail Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neotrail Therapeutics Inc filed Critical Neotrail Therapeutics Inc
Publication of AU2021282287A1 publication Critical patent/AU2021282287A1/en
Assigned to NeoTrail Therapeutics, Inc. reassignment NeoTrail Therapeutics, Inc. Request for Assignment Assignors: HOOKIPA BIOTECH GMBH
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2021282287A 2020-05-29 2021-05-12 Cancer treatment strategies using arenavirus vectors Pending AU2021282287A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063032362P 2020-05-29 2020-05-29
US63/032,362 2020-05-29
US202163173155P 2021-04-09 2021-04-09
US63/173,155 2021-04-09
US202163175842P 2021-04-16 2021-04-16
US63/175,842 2021-04-16
PCT/EP2021/062728 WO2021239471A1 (en) 2020-05-29 2021-05-12 Cancer treatment strategies using arenavirus vectors

Publications (1)

Publication Number Publication Date
AU2021282287A1 true AU2021282287A1 (en) 2023-01-05

Family

ID=75914543

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021282287A Pending AU2021282287A1 (en) 2020-05-29 2021-05-12 Cancer treatment strategies using arenavirus vectors

Country Status (12)

Country Link
US (1) US20230346906A1 (https=)
EP (1) EP4157342A1 (https=)
JP (1) JP2023527083A (https=)
KR (1) KR20230046278A (https=)
AU (1) AU2021282287A1 (https=)
BR (1) BR112022024404A2 (https=)
CA (1) CA3184791A1 (https=)
CR (1) CR20220602A (https=)
IL (1) IL298420A (https=)
MX (1) MX2022014725A (https=)
PE (1) PE20240647A1 (https=)
WO (1) WO2021239471A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604695B1 (en) 2007-12-27 2022-11-16 Universität Zürich Replication-defective arenavirus vectors
CN115058452A (zh) 2013-12-03 2022-09-16 霍欧奇帕生物科技有限公司 Cmv疫苗
EP3307308A2 (en) 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
WO2023152116A1 (en) * 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
AU2024343172A1 (en) 2023-09-15 2026-03-05 Gilead Sciences, Inc. Arenavirus formulations, methods and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3218504T (lt) 2014-11-13 2020-09-10 Université De Geneve Trijų segmentų arenavirusai kaip vakcinos vektoriai
EP3307308A2 (en) * 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
RS63546B1 (sr) 2015-11-12 2022-09-30 Hookipa Biotech Gmbh Čestice arenavirusa kao vakcine protiv kancera
US20190135875A1 (en) 2016-05-18 2019-05-09 Hookipa Biotech Gmbh Tri-segmented pichinde viruses as vaccine vectors
AU2018247958A1 (en) * 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors

Also Published As

Publication number Publication date
IL298420A (en) 2023-01-01
JP2023527083A (ja) 2023-06-26
WO2021239471A9 (en) 2022-01-13
KR20230046278A (ko) 2023-04-05
EP4157342A1 (en) 2023-04-05
WO2021239471A1 (en) 2021-12-02
CR20220602A (es) 2023-05-16
PE20240647A1 (es) 2024-04-04
MX2022014725A (es) 2023-02-09
BR112022024404A2 (pt) 2023-02-07
CA3184791A1 (en) 2021-12-02
US20230346906A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
US20230346906A1 (en) Cancer treatment strategies using arenavirus vectors
Yarchoan et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial
Galon et al. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
US11065285B2 (en) Biomarkers and combination therapies using oncolytic virus and immunomodulation
Westdorp et al. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
AU2017268822B2 (en) Neoepitope vaccine compositions and methods of use thereof
Ranki et al. Phase I study with ONCOS-102 for the treatment of solid tumors–an evaluation of clinical response and exploratory analyses of immune markers
Brahmer et al. JNJ-64041757 (JNJ-757), a live, attenuated, double-deleted Listeria monocytogenes–based immunotherapy in patients with NSCLC: results from two phase 1 studies
EP4031573A1 (en) Combination of a poxvirus encoding hpv polypeptides and il-2 with an anti-pd-l1 antibody
Pham et al. First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)
JP2021516957A (ja) パラポックスウイルスベクター
US20240047009A1 (en) Nant cancer vaccine strategies
AU2016263147A1 (en) Recombinant oncolytic viruses and uses thereof
TW201038943A (en) Biomarker for monitoring patients
CN116490205A (zh) 使用沙粒病毒载体的癌症治疗策略
Tan et al. 269 Tumoral and peripheral landscape of Viral-versus Carcinogen-Driven Head and Neck Cancer
Rossi et al. Therapeutic vaccines targeting HPV epitopes in human papillomavirus–positive oropharyngeal cancer: a critical review
JP2025500258A (ja) 変異型ｃａｌｒ及びｊａｋ２に基づくワクチン並びにこれらの使用
US20150177241A1 (en) Biomarkers of immune response in mucosal lesions and their use with therapeutic vaccination
Hellner et al. A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-Risk Human Papillomavirus Vaccine in Women with Low-grade Cervical Lesions
Makrinos et al. A multivalent mRNA-LNP therapeutic vaccine with broad cross-genotype immunogenicity elicits clearance of HBV infected hepatocytes
WO2025007059A1 (en) Engineered chimeric fusion protein compositions and methods of use thereof
WO2026046208A1 (zh) 中性粒细胞数在预测溶瘤病毒治疗肿瘤的疗效中的应用
WO2024138754A1 (zh) 一种hla-a*11:01限制性抗原点替换方法、获得的多肽及其应用
WO2025149656A1 (en) Treatment and prevention of lung cancer

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NEOTRAIL THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): HOOKIPA BIOTECH GMBH